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Abstract 
 
Malaria continues to be a challenging problem in the developing world, and the 
burden of this life threatening disease continues to be borne by young children  
living in Sub Saharan Africa. One of the biggest challenges to the prevention and 
control of this problem lies in accurately diagnosing malaria, and distinguishing it 
from the many other febrile illnesses which present in children in this age group. 
 
Liberia is a West African country with a high burden of malaria. Very little is 
known about the presentation of severe malaria in children aged 5 years old and 
younger in Liberia.  We undertook a prospective, hospital -based study of 
children 5 and under presenting to JKF Medical Center, the national referral 
hospital, with fever and signs and symptoms consistent with malaria. The aims of 
our study were to determine: 1) the frequency of confirmed malaria cases, 2) the 
frequency of non-malaria diagnoses, 3) the prevalence of anti-malarial drug 
resistance mutations, 4) the presence of other life threatening etiologies of febrile 
illness such as S. typhii and Dengue virus and 5) immunological profiling 
associated with severe malaria. 
 
We analyzed clinical and laboratory data from 462 children age 5 and under who 
presented to the national referral hospital in Monrovia, Liberia with signs and 
symptoms consistent with malaria over a one year period. Key findings included 
 4 
determining the demographic factors most closely associated with severe malaria 
in this population (age  > 1yr and urban environment) and those that were 
negatively associated with the development of severe malaria (prior episodes of 
malaria, use of bednets and use of anti malarial medications prior to 
presentation).  The clinical symptoms most closely associated with severe 
malaria in this population were found to be headache and vomiting. 
 
We found that 33% of children admitted and treated for severe malaria did not 
test positive for malaria by rapid diagnostic testing (RDT) or blood smear.  These 
children had a case fatality rate that was 5 times higher than their RDT positive 
counter parts.  Of the RDT negative children, 2 tested positive for salmonella 
typhii, but were not treated for this pathogen.  Upon discharge from the hospital, 
11% of children had resolved their symptoms, but had not cleared their malaria 
parasites.   
 
These findings will help to identify the children who present with true severe 
malaria in Liberia.  They also underscore the need to expand diagnostic 
capabilities to determine which other types of pathogens cause febrile illness in 
this population, so that adequate treatment can be extended to these patients.  
 
The immunoprofiles of these children revealed 3 IgM antibodies (AMA-1, CSP 
and LSA-1) that were associated with the development of severe malaria. These 
 5 
antibodies also appear to be associated with initial infection with malaria.  Such 
data will help to identify antigens could be potential targets for malaria vaccines, 
and which can play an important role in the development of new malaria 
diagnostics for this population. 
 
  
 6 
 
Table of Contents 
                 Page 
 
 
Acknowledgements        2 
 
Abstract         3  
    
List of Tables & Figures       5  
     
Introduction         6 
 
Methods        11 
 
Results        20 
 
Discussion        40 
 
Appendices        57 
 
References        59 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
 
List of Tables and Figures 
 
Figure 2.1:   Study Design 
Table 3.1:   Patient Enrollment 
Table  3.1:   Age Distribution of RDT positive vs RDT negative patients 
Table  3.1 :  Demographic and Clinical Characteristics of the Study Population based on RDT 
test results 
Table  3.2 :  Demographic and Clinical Characteristics of patients with severe versus  
uncomplicated Malaria 
Figure 3.3:  Logistic regression analysis of demographic and clinical factors associated   
with severe malaria 
Figure 3.4:  Results of febrile case investigation 
Table  3.3:  Clinical and demographic characteristics of patients who did not clear parasites 
Table  3.4:  Logistic Regression analysis of IgG antibodies associated with severe malaria 
Table  3.5:  Logistic regression anaylsis of IgM antibodies associated with severe malaria 
Figure 3.5:  Forest plot of IgG and IgM antibodies associated with severe malaria 
Figure 3.6:  Anti-malaria IgG and IgM present at birth, with first infection and with recurrent  
infection 
Table  3.6: Correlation coefficients of IgM versus IgG in RDT positive patients 
Table  3.7: Correlation coefficients of IgM versus IgG in RDT negative patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
 
 
Chapter I: Introduction 
 
According to the World Malaria Report 2016, there were 214 million cases of 
malaria globally in 2015 and 438,000 malaria deaths (1). The burden of malaria 
deaths has been heaviest in the WHO designated African Region, where an 
estimated 90% of all malaria deaths occurred.  Secular trends in death rates, and 
total malaria deaths, are dominated by West Africa, which accounts for the 
highest number of all malaria deaths in Africa (31%). The burden of malaria 
deaths in Sub Saharan Africa (SSA) continues to be shouldered by children less 
than 5 years old, who account for more than two thirds of all malaria deaths, and 
the highest number of deaths and highest death rates on the African continent 
(2). 
  
There are several challenges to accurately diagnosing and treating malaria in 
SSA. In low resource countries, where there is a high burden of malaria, 
differentiating malaria from other causes of febrile illness can be challenging. 
Many of the signs and symptoms of malaria are shared with other infectious 
diseases that are prevalent in the region. A striking example is the recent Ebola 
Virus outbreak in Liberia, which posed many diagnostic and management 
challenges, since Ebola Virus Disease (EVD) shares many of the same 
symptoms as malaria (3). Other etiologies of febrile illness, such as Salmonella 
typhi and viral infections, are also prevalent, but severely constrained laboratory 
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resources make a definitive diagnosis and effective treatment difficult to 
determine by clinical findings alone.   
 
Many studies have demonstrated that in high malaria transmission areas, a large 
percentage of the population can carry malaria parasites asymptomatically, 
without showing signs of the disease (4). Patients develop partially protective 
immunity against the parasite after repeated infection, and will test positively on 
malaria diagnostic tests, even though malaria may not be the cause of their acute 
illness. This can cause confusion when patients present with febrile illness, since 
these patients can be treated for malaria, while the true cause of their illness may 
be overlooked.  The development of tolerance to the malaria parasite in this 
setting is thought to occur in young children, as they become repeatedly exposed 
to the malaria parasite (5).  A better understanding of the development of this 
natural immunity is useful in learning how to develop targets for a malaria 
vaccine. 
  
Finally, the development of Plasmodium falciparum antimalarial drug resistance 
is one of the major obstacles in the fight against malaria (6). Recent studies 
combining data sets from the Global Burden of Disease Study (7) and the 
Malaria Atlas Project (8) demonstrate that various preventive and treatment 
measures, including the use of insecticide treated bed nets, malaria rapid 
diagnostic tests (RDT), and treatment using artemisinin-based compounds have 
 10 
been responsible for a large decrease in the total number of malaria deaths since 
2010, and a decrease in the incidence rate of new malaria cases in the African 
region. However, concern about achieving sustained malaria control and 
eventual elimination have arisen in light of the recent development of artemisinin 
resistant parasites in Southeast Asia (9). Timely information on the scope of 
antimalarial drug resistance is essential in advancing malaria control programs. 
Using molecular markers it is possible to screen parasites for the gene mutations 
that convey antimalarial drug resistance. For example, a study in Ghana in 2005 
demonstrated the presence of mutations in the pfcrt and pfmdr1 genes 
associated with chloroquine and possibly with amodiaquine and mefloquine 
resistance (10).  
  
In order to monitor global malaria control, countrywide programs have been 
initiated.  Liberia is a West African country with a high clinical and public health 
burden of malaria. Recent data from the President’s Malaria Initiative shows that 
malaria continues to be a significant problem in Liberia, and accounts for more 
than 40% of outpatient visits and 33% of inpatient deaths (11). All geographic 
areas are at risk and transmission is perennial.  The major parasite species are 
Plasmodium falciparum (>90%), P. ovale, and P. malariae. The most recent 
Liberian Demographic and Health Survey performed in 2013 (12) showed a 
malaria prevalence rate of 28% nationally, with considerable variation by region, 
ranging from 17% in the south central region (which includes the capital city 
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Monrovia) to 49% in the southeast region.  Based on results from the Liberian 
Malaria Indicator Surveys in 2011 (13), the prevalence of malaria parasitemia in 
children under age five by RDT was 66% in 2005, 37% in 2009,  and 45% in 
2011; the prevalence rate as measured by microscopy was 32% in 2009 and 
28% in 2011. The Ebola epidemic that struck West Africa late in 2014 disrupted 
much of the health care system, and it is hypothesized that this may have led to 
an even greater incidence of malaria parasite frequency; however, due to 
disruptions in disease reporting, little recent data exists (11). 
  
Pilot data obtained at the national referral hospital, JFK Medical Center from 
2009-2011, suggests that 42% of hospitalizations for children less than 5 years 
old were for the treatment of malaria. Approximately 20 % of children who were 
presumed to have malaria did not meet the WHO case definition, raising the 
possibility that alternative febrile illnesses may have been under diagnosed. 
Furthermore, an additional 5% of patients did not respond to standardized 
antimalarial treatment, raising the possibility that drug resistance already exists in 
Liberia and may contribute to treatment failures (unpublished data).  Little is 
known about the prevalence of anti-malarial drug resistance mutations in malaria 
parasites found in Liberia. 
  
Overall, little has been published about the clinical presentation of malaria in 
children in Liberia and etiology of alternative diagnoses. The WHO has devised a 
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case definition for the diagnosis of severe malaria (14), but this working case 
definition has not been validated in this setting.  Little is also known about the 
effectiveness of treatment for malaria in Liberians and other potentially life-
threatening causes of febrile illness that may exist in this population.  Since 
Liberia is a high intensity transmission region for malaria, it is also an ideal 
setting to evaluate the development of natural immunity to malaria and how sero-
surveys could be used to monitor malaria transmission and malaria control efforts 
– as well as improve diagnoses.   
  
 
Study Aims: 
 
The goals of this prospective, hospital-based, observational study were to 
provide the following information on children admitted to JFK medical center with 
febrile illness: 1) the frequency of confirmed malaria cases; 2) the frequency of 
non-malaria diagnoses; 3) the prevalence of anti-malarial drug resistance 
mutations 4) the presence of other life threatening etiologies of febrile illness 
such as S. typhii and Dengue virus; and 5) the immunological profiles of children 
presenting with severe malaria.  
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Chapter II. Methods 
 
Study overview 
We carried out a prospective longitudinal study of the clinical course for children 
seen for, and/ or admitted with, suspected malaria over a 12-month period from 
June 2013 through May 2014 at the JFK Medical Center  (Figure 2.1). For 
comparison, we recruited both children being admitted for severe malaria and 
also outpatients with uncomplicated presentations, so that we could compare 
patients with severe versus uncomplicated malaria. 
 
 
Figure 2.1: Study Design 
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Study setting 
The study site, JFK Medical Center, is a tertiary care facility situated in Monrovia, 
the capital city, and is the National Referral Hospital for the country. Complicated 
cases of severe malaria are often referred to this hospital for management.  The 
under 5 (U5) unit consists of 30 beds with a census of about 250 admissions per 
month. Children admitted to this unit are under 5 years of age, and approximately 
42% of these admissions are for treatment of malaria. The outpatient clinic sees 
approximately 1,800 children per month and it is estimated that 40% are seen for 
suspected malaria. 
  
Patient recruitment 
Inclusion criteria for the inpatient study included the following: 1) presentation to 
the pediatric  “U5” unit at JFK Medical Center; 2) signs and symptoms upon 
admission consistent with severe malaria including prostration, weakness, 
impaired consciousness, seizures, respiratory distress, and treatment initiated for 
severe malaria; 3) parental written consent; and 4) age range birth to 5 years of 
age. Exclusion criteria included children currently on treatment for HIV (since 
anti-retroviral medication may partially treat malaria) or other complicated 
illnesses, which may affect immune function, such as cancer or severe 
malnutrition. 
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Inclusion criteria for outpatients recruited to the study included the following: 1) 
presentation to the outpatient clinic with fever and suspected malaria;  2) parental 
written consent; and 3) age range birth to 5 years of age.   
  
Data Collection 
After informed consent was obtained, a research nurse collected demographic 
and clinical information from an in-person parent interview and chart review 
(Appendix 1).  Blood was obtained for malaria diagnosis, as per usual JFK 
protocol, and at this time, an additional blood sample was obtained for future 
research studies. 
  
Children who were hospitalized were also asked to provide additional clinical and 
laboratory data, either on hospital day 3 or upon discharge, whichever came first, 
to investigate the clearance of parasites and resolution of presenting symptoms. 
  
All data were transferred to a database that was created in REDCap. 
  
Clinical Assessment 
A research nurse who spoke local dialects interviewed parents and obtained 
demographic information and information about clinical signs and symptoms of 
malaria. A standardized data collection form was utilized which included WHO 
criteria of severe malaria. Parents were also asked about other common signs 
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and symptoms of disease, and were asked about any additional symptoms not 
listed on the form (Appendix I). The form was used for data collection for both 
outpatient and inpatient study subjects. 
  
At the time of hospital discharge, or on hospital day 3, whichever was first, the 
research nurse obtained additional clinical information from inpatient study 
subjects to assess treatment related outcomes. Blood was obtained for a malaria 
smear to assess clearance of parasites. 
  
Clinical Laboratory Studies. 
 In Liberia, the U5 clinical lab was utilized to perform malaria diagnostic lab 
studies.  The First Response rapid diagnostic test (RDT), manufactured by 
Premier Medical Solutions, India, which tests for the malaria HRP2 antigen, was 
used to diagnose patients with malaria.  This test is highly sensitive and specific 
for diagnosis of P. falciparum infection, but will also detect P. ovale, so that all 
known species of malaria in Liberia are detected using this test. Patients with 
malaria will continue to test positive for 2-4 weeks after initiation of treatment. 
 
 Admitted patients also had a malaria smear and hemoglobin level performed, as 
per standard protocol. The presence of malaria parasites was determined using 
Giemsa stained slides and read by trained microscopists. Clearance of parasites 
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was assessed by repeating the malaria slide on hospital discharge or on hospital 
day three. 
  
Clinical management 
 The majority of patients were seen initially by a trained medical officer in the 
outpatient department of JFK Medical Center.  Patients who were acutely ill and 
needed urgent medical attention were brought directly for inpatient admission. 
Many of these patients would be started presumptively on malaria treatment, due 
to the acuity of their illness.  Outpatients who were found to be RDT positive, but 
judged by the medical officer providing care to not have symptoms or signs of 
severe malaria, were treated at home with oral ACT (artemether/lumefantrine), 
one pill daily for 3 days, according to a standard protocol. 
  
Patients who were judged to have signs and symptoms of severe malaria (RDT 
positive, symptoms of severe malaria by WHO criteria) were referred for inpatient 
admission.  These patients received a malaria smear and hemoglobin level prior 
to initiation of treatment.  Inpatients were treated using either intravenous quinine 
or intravenous artusenate. At the time that this study was performed, Liberia 
national guidelines had recently changed to require intravenous artemisinin 
based compounds be used for inpatient treatment of severe malaria. However, 
early in the study, and at some points during the study when stockouts occurred, 
children were treated with intravenous quinine x 3 IV doses. 
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After completing the specified course of intravenous treatment, children were 
discharged home with an additional 3-day course of oral ACT or quinine, 
depending on which treatment they had received intravenously.  Typically, there 
is no investigation to determine if patients have cleared their parasitemia upon 
discharge. 
  
Research laboratory methods 
Finger prick or venous blood samples for future investigations were obtained 
from enrolled study participants and collected using sterile technique into BD 
anti-coagulated Microtainer tubes (~ 500 µl) and also by collecting blood drops 
onto filter papers. Blood samples obtained on admission for research purposes 
were centrifuged in the JFK laboratory to separate plasma from blood cell pellet.  
The samples were then frozen in -20C freezer until transport. Additional blood 
spots on filter paper were obtained, packaged with desiccant and stored in a 
similar manner. Samples were transferred by air carrier to UMass Medical School 
for further investigation. 
  
Molecular techniques: For drug resistance screening, we performed DNA 
isolation from the pooled filter paper specimens using commercially available 
DNA extraction kits (Qiagen). PCR primers and restriction enzymes were 
purchased for the amplification and detection of known malaria drug resistance 
mutations such as pfcrt and pfmdr1 genes associated with chloroquine and 
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possibly with amodiaquine and mefloquine resistance, the mutations in the dhps 
and dhfr which are associated with sulfadoxine pyrimethamine resistance, and 
the Kelch 13 mutations which are associated with artemesinin resistance. 
Methods for performing DNA amplification and isolation were performed using 
previously published methods (15). 
  
Immunological studies.  Plasma was used for serological profiling. We utilized a 
panel of 8 malaria antigens and antigenic-strain variants using Luminex bead-
based suspension assay technology (BioRad).  This method enables the 
detection of a patient antibody titer with the use of a capture antigen conjugated 
to a fluorescent microsphere, followed by identification using a fluorescently 
labeled secondary anti-human IgG or IgM antibody.  Thus, serum from study 
participants was analyzed for IgG and IgM anti-malaria antibodies to a panel of 
malaria antigens including the pre-erythrocyte antigens Liver stage antigen 1 
(LSA1) and Circumsporozoite Protein (CSP), the blood stage antigens Apical 
Membrane Antigen (AMA-1), Histidine Rich Protein 2 (HRP2), Merozoite Surface 
Protein 1 (MSP-1) 3D7, FUP and FVO allelic variants and the transmission 
blocking antigen, Cell Traversal Protein (Celtos) (16,17).  
  
Salmonella typhi detection. Plasma samples from patients with severe malaria 
were also analyzed for the presence of IgM antibodies specific to Salmonella 
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typhi. This was accomplished using commercially available kits (Corgenix), which 
were highly sensitive for detection of this pathogen. 
  
Dengue virus detection. Plasma samples from patients who were hospitalized but 
RDT negative were used to detect presence of Dengue virus NS-1 antigen and 
IgM antibodies, using techniques described previously (19), and commercially 
available kits (Corgenix). 
  
Data Analysis 
We performed descriptive statistics (means, medians, standard deviations, and 
95% confidence limits) on all variables of interest. We explored the relationship 
among the individual covariates with malaria cases (hospitalized patients who 
achieved resolution of symptoms and clearance of parasitemia by discharge) and 
also between cases and non-cases, and patients with severe (patients who were 
RDT positive, and with symptoms of severe malaria) versus mild disease 
(patients who were RDT positive, but with no symptoms of severe disease). As 
appropriate, between group differences were examined using chi-square tests of 
independence (categorical variables), t-tests (continuous variables) or the 
equivalent non-parametric tests depending on the distribution of the variables.   A 
two-sided p-value <0.05 was considered to be statistically significant. 
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 We performed logistic regression analysis to determine which demographic 
clinical characteristics and immunological profiles that were most significantly 
associated with severe malaria (RDT positive inpatients).  Results were age 
adjusted, since age was noted to be a significant confounder.  For those 
antibodies that demonstrated a large range in mean fluorescent intensity, the 
levels were broken down into high and low levels, to ascertain whether higher 
antibody titers were significantly associated with severe malaria onset. Data were 
analyzed using SPSS. 
  
Ethical Approval 
IRB approval was obtained from the Institutional Review Board at JFK Medical 
Center, Monrovia, Liberia and from the University of Massachusetts Medical 
School, Worcester, MA, USA. 
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Chapter III:  Results 
 
Patient Enrollment  
During the period from June, 2013 to May, 2014, a total of 477 children ranging 
in age from 0-5 years who presented to JFK Medical Center in Monrovia with 
fever and suspected malaria were enrolled in this study.  Of these, 232 (50.2%) 
tested positive by RDT for malaria.  Of those testing positive, 70.8% met the 
WHO criteria for severe malaria and were admitted to the hospital for intravenous 
treatment as previously described.  The remaining study participants had 
uncomplicated infections and were treated on an outpatient basis with oral ACT 
(Figure 3.1). 
 
 
  
 
Figure 3.1: Patients enrolled in study 
478	patients	Enrolled	June	2013-May	2014	
462	patients	Analyzed			
215																						Outpatient	
	148	RDT	-							68	RDT	+														(Mild	Malaria)	
	246																					Inpatient		
81	RDT	-								165		RDT	+	(Severe	Malaria)		
16	patients	missing	data	(5%)	
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Figure 3.2: Age distribution of respective patient groups .  Upper:  Patients with 
RDT positive test results versus RDT negative results. Lower: RDT positive 
hospitalized patients (Severe Malaria) versus RDT positive outpatients 
(uncomplicated malaria) 
 
% of Patients  
% of Patients 
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Table 3.1: Demographic and Clinical Characteristics  
Based on Rapid Diagnostic Test (RDT) results 
 
Characteristic RDT (+) 
(n= 232) 
RDT( –) 
(n=230) 
P value 
 
Age 
(mean, years) 
2.1 
  
  
1.4      <0.001 
 
 
n % n %  
Female 107 
 
46.1 105 45.7 0.93 
Urban 137 59.1 85 37.0 <0.001 
Regular bed net 
use 
  
50 
 
21.6 82 
 
35.7 <0.001 
Treated for malaria 
in past  
92 
 
40.0 93 
 
40.4 0.92 
Anti-malarial use 
prior to presentation 
44 
 
19.1 60 
 
26.1 0.07 
Headache 179 
 
77.0 117 
 
50.9 <0.001 
Prostration/ 
Weakness 
 
149 
 
64.2 98 
 
42.6 <0.001 
Impaired 
Consciousness 
19 
 
8.20 10 
 
4.3 0.12 
Pallor 0 
 
0.00 
 
2 
 
0.01 0.24 
Seizure 
 
57 
 
24.5 26 
 
11.3 0.002 
Cough 142 
 
61.2 128 
 
55.7 0.26 
Diarrhea 50 
 
22.3 51 
 
22.2 0.91 
Jaundice 2 
 
0.01 2 
 
0.01 1.00 
Respiratory 
Distress 
38 
 
16.4 17 
 
7.39 0.013 
Vomiting 90 38.8 47 
 
20.4 <0.001 
Febrile days (mean) 
 
3.75 3.66 0.68 
Hgb (mg/dL) 
(mean) 
9.42 10.52 0.04 
Parasitemia  
0 
1-2+ 
3-4+ 
No smear 
No Data 
 
10 
86 
69 
9 
22 
 
0 
0 
0 
 
 
 
ND 
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Demographic characteristics and clinical characteristics of children with malaria.   
Demographic characteristics. The average age of patients enrolled in the study 
was 1.6 years.  There were a significantly greater proportion of younger patients 
less than one year of age in the RDT negative group, 52% vs. 26% respectively.  
There were also a significantly greater proportion of patients less than one year 
of age who had uncomplicated versus severe disease, 52% versus 17%, 
respectively (Figure 3.2). 
 
Less than one half of study patients (46%) were female and 48% of study 
patients were from Monrovia.  Only 31% of parents reported regular bed net use, 
40% of children had a history of treatment or hospitalization for malaria in the 
past, and 60% had no reported prior history of malaria. Overall, 22% had used an 
antimalarial medication obtained from a clinic or pharmacy prior to presentation 
to treat the current febrile illness. Of these, 26% were RDT negative patients and 
19% were RDT positive patients. Since HRP2 antigen and RDT positivity persists 
from  2-4 weeks after treatment of active infection,  it is unlikely that the RDT 
negative patients, who typically presented with fever for less than 4 days, were 
cases of malaria. 
  
Children who tested RDT positive were older and were more likely to be from an 
urban environment versus those who were RDT negative.   Children who tested 
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negative for malaria were more likely to be sleeping under bed nets regularly as 
compared with their RDT positive counterparts (Table 3.1, figure 3.3). 
  
Demographic characteristics associated with severe malaria (WHO criteria, 
inpatient admission) versus those uncomplicated malaria (outpatient treatment) 
are shown in Table 3.2 and Figure 3.3. Those from urban areas were more likely 
to present with severe malaria. Alternatively, patients with uncomplicated disease 
were more likely to have been using bed nets regularly, used an antimalarial 
medication prior to presentation, and were more likely to have been treated for 
malaria in the past when compared with those who presented with severe 
disease.  
  
Clinical characteristics.  Clinical signs and symptoms were elicited from all study 
participants   The most common symptoms in this population of children, 
presenting with febrile illness and suspected of having malaria, were headache 
(64%), cough (58%), prostration and weakness (53%), vomiting (29%), diarrhea 
(22%), seizure (18%), respiratory distress (12%), and impaired consciousness 
(6%) (Table 3.1), In comparing children who were diagnosed with malaria  
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Figure 3.3: Logistic regression analysis of demographic and clinical features associated 
with RDT positive patients versus RDT neg (top panel) and with RDT positive 
outpatients (uncomplicated malaria) versus RDT positive inpatients  (severe malaria) 
(bottom panels). 
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Table 3.2: Demographic and Clinical Characteristics of Patients with Severe (inpatient)  
Versus Uncomplicated (outpatient) Malaria 
  
Characteristic RDT + Inpatient 
(n= 165) 
RDT + Outpatient 
(n=68) 
   P value 
 
Age   
(Mean, years) 
2.41 
 
1.37        <0.001 
 n % n %  
Female 68 41.2 39 57.3 <0.001 
Urban 104 
 
63.0 34 
 
50.0 <0.001 
Regular bed net 
use 
  
20 
 
12.1 30 
 
44.1 <0.001 
Treated for 
malaria in past   
48 
 
29.0 45 
 
66.1 
 
<0.001 
Anti-malarial use 
prior to 
presentation 
8 
 
6.99 30 
 
44.8 <0.001 
Headache 156 
 
94.0 24 
 
35.3 <0.001 
Prostration/ 
Weakness 
 
133 
 
80.1 16 
 
23.5 <0.001 
Impaired 
Consciousness 
18 
 
10.8 1 
 
0.00 0.016 
Pallor 0 
 
0.00 
 
0 
 
0.00 1.00 
Seizure 
 
54 
 
32.5 3 
 
2.94 <0.001 
Cough 107 
 
64.5 35 
 
48.5 0.08 
Diarrhea 37 
 
22.3 13 
 
17.6 0.73 
Jaundice 1 
 
0.01 0 
 
0.00 1.000 
Respiratory 
Distress 
36 
 
21.7 0 
 
0.01 <0.001 
Vomiting 81 
 
48.8 9 
 
13.2 <0.001 
Febrile days  
(mean) 
3.70 3.81           0.67 
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(RDT positive) versus those who were  RDT negative, the clinical symptoms 
significantly associated with a diagnosis of malaria were headache and vomiting  
(Figure 3.3). Vomiting was not a symptom on the original checklist; rather it was 
a symptom that was added when patients were asked about “other symptoms”. It 
was found to be significantly associated with testing RDT positive in this 
population.  The only clinical symptom significantly associated with being RDT 
negative was diarrhea. 
  
Clinical data were also analyzed to determine if there were clinical symptoms that 
were associated with severe malaria (RDT positive inpatients) versus 
uncomplicated disease (RDT positive outpatients) (Table 3.2). Headache, 
prostration, weakness and seizures were associated with severe disease. The 
symptoms most significantly associated with uncomplicated disease included 
diarrhea and cough (figure 3.3). 
 
Febrile Case Investigations 
Patients who were admitted to the hospital with febrile illness and a presumed 
diagnosis of malaria, and were being treated for malaria, were assessed on 
admission and followed through discharge or hospital day 3 to determine their 
outcomes (Figure 3.4).  
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Figure 3.4: Results of febrile case investigations 
 
 
 
Among the 246 patients admitted and presumptively treated for malaria, 165 
(67%) tested positive for malaria by RDT.  There were 5 deaths in this young 
patient cohort, including 1 in the malaria positive group and 4 in the malaria 
negative group. The hospital case fatality rate for patients with RDT positive 
malaria was 1.2%; for those who RDT tested negative, but were still treated for 
malaria, the case fatality rate was 4.9%. 
  
246	Admitted	with	Presumed	Severe	Malaria	
Demographic,	Clinical	&	Lab	Data	Collected	
165	RDT	or	Smear	
Positive	for	Malaria	
Day	3:			Clears	Parasites	Symptoms	resolved	
142	ConVirmed	Case	No	further	workup	
Day	3:	19	did	not	clear	Parasites	
	Screen	for	Drug	Resistance	Mutations	
Day	3:		Symptoms	Not	resolved					No	Co	Morbid	Infection?	
0	Dengue	Virus	0		S.	Typhii	
81	RDT	or	Smear	
Negative	for	Malaria	
?	Alternative	Diagnosis	
0	Dengue	Virus	3		S.	Typhii	
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Of the 165 patients who were admitted and tested positive for malaria, 142 (89%) 
responded effectively to treatment (resolved symptoms, parasite cleared on day 
3 smear).   However, 19 patients (11%) admitted with RDT positive malaria did 
not clear their parasites after treatment and harbored parasite levels ranging from 
1+-4+. Nevertheless, the patients in this group had resolved their acute 
symptoms by day 3 and were discharged home, with malaria positive blood 
smears (parasitemia is not routinely re-tested after symptoms resolve). The 
average age of this cohort was 28 months, and only 2 were less than 9 months 
old. The majority of these patients were treated with intravenous Artusenate as a 
monotherapy (Table 3.3).  
  
 
Patients who were hospitalized, but were RDT negative, were screened for two 
alternative causes of febrile illness, namely Dengue virus and Salmonella typhi. A 
total of 3 patients (3.7%) who were RDT negative tested positive for Salmonella 
typhi IgM by ELISA.   All of these children, who were older than 3 years, were 
treated with anti-malarials, and none received antibiotics because this test was 
done retrospectively as part of this pilot research project.  Of the 3 patients, 2 
resolved symptoms and were discharged on day. One patient did not resolve 
symptoms immediately and was hospitalized for 7 days. The RDT negative 
patients were also tested retrospectively for Dengue virus by ELISA to NS1 
antigen, but none tested positive. 
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     *ND- Not done 
   **NR- Not recorded 
 
 
 
 
 
 
 
 
 
 
 
	
Table	3.3:		Clinical	and	demographic	characteristics	of	patients	who	did	not	clear	parasitemia	on	discharge	
	
	
Patient	
Age	
In	
mos.	 Sex	
Admit	
Date	 Region	
Number	
of	
malaria	
infection
s	in	past	
RDT	on	
Admit	
Level	of	
Parasitem
ia	on	
Admit	
	(0-4+)	
Medication	
Used	
Level	of		
Parasitemia		
On	Day	3	(0-4+)	
	
1	 52	 Male	 11/11/13	 Montserrado	 3	 Positive	 1+	 Artusenate,		 4+		
	
2	 45	 Male	 7/24/13	 Montserrado	 0	 Negative	 ND	*	 Quinine	 2+	
	
3	 37	 Female	 11/6/13	 Montserrado	 0	 Positive	 4+	 Artusenate,		 4+	
	
4	 		 Male	 11/6/13	 Montserrado	 0	 Negative	 ND	 Artusenate,		 1+	
	
5	 55	 Male	 11/7/13	 NR**	
	
0	 Negative	 ND	 NR**	 1+	
	
6	 25	 Male	 11/7/13	 Montserrado	 1	 Negative	 ND	 NR	 1+	
	
7	 38	 Male	 11/7/13	 Montserrado	 0	 ND	 ND	 NR	 2+	
	
8	 37	 Female	 11/12/13	 Bong	County	 0	 Positive	 4+	 NR	 1+	
	
9	 17	 Male	 11/20/13	 Lofa	
	
1	 Negative	 ND	 Artusenate,		 1+	
	
10	 8	 Male	 12/4/13	 Montserrado	 0	 Positive	 2+	 NR	 1+	
	
11	 20	 Male	 12/18/13	 Montserrado	 1	 Negative	 ND	 Artusenate,		 1+	
	
12	 23	 Male	 1/14/14	 Montserrado	 0	 Positive	 1+	 Artusenate,		 1+	
	
13	 1	 Male	 1/21/14	 Montserrado	 2	 Positive	 ND	 Artusenate,		 1+	
	
14	 40	 Male	 2/23/14	 Bomi	County	 0	 Positive	 3+	 Artusenate,		 3+	
	
15	 		 Male	 2/24/14	 Montserrado	 0	 Negative	 ND	 Artusenate	 1+	
	
16	 19	 Male	 2/24/14	 Grand	Cape		 0	 Positive	 1+	 Artusenate	 1+	
	
17	 33	 Female	 2/28/14	 Grand	Bassa	 2	 Negative	 ND	 Artusenate	 1+	
	
								18																		25	 Male	 2/28/14	 Bong	 0	 Positive	
	
2+	 Artusenate	 1+	
	
19	 9	 Male	 4/3/14	 Grand	Bassa	 0	 Negative	 2+	 Artusenate,		 1+	
  * 
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Anti-malarial drug resistance 
In our original study design, patients who had not cleared their parasitemia by 
hospital day 3 were to be tested for anti-malarial drug resistance. Unfortunately, 
due to the onset of the EVD outbreak, we could not transport all of our samples 
out of Liberia for analysis due to perceived risk and so we were not able to 
perform drug resistance studies on blood collected from individual patients. 
However, we were able to pool DNA from a random sampling of 100 RDT 
positive inpatients, at time of diagnosis, to screen for drug resistance in this 
population.  DNA was extracted from filter paper specimens, pooled and PCR for 
the four drug resistance mutations was performed.  No known drug resistance 
alleles were found.  
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Table 3.4:  Logistic Regression Analysis IgG Antibody 
Associated with Severe Malaria (adjusted for age) 
 
  IgG Antibody OR * 95% CI 
AMA 1 FVO 3.29 (low titer) 
2.76 (high titer) 
1.17-9.22 
1.16-6.60 
Celtos 3.31 0.99-11.1 
CSP 2.72 0.32-23.2 
HRP11 2.43 (low titer) 
5.09 (high titer) 
0.86-6.83 
1.45-17.8 
LSA1 3.42 
 
0.60-19.4 
 
MSP1 3D7 3.33  (low titer) 
3.17  (high titer) 
 0.91-12.3 
1.53-6.57 
MSP1 FVO 4.39  (low titer) 
3.98  (high titer) 
1.22-15.8 
1.75-9.02 
MSP FUP 3.06  (low titer) 
4.27  (low titer) 
1.06-8.83 
1.89-9.63 
 
Table 3.5: Logistic Regression Analysis: IgM antibody associated 
with severe malaria (adjusted for age) 
 IgM Antibody OR* 95% CI 
AMA 1 1.61 (low titer) 
8.33 (high titer) 
0.75-3.45 
1.05-65.9 
Celtos 1.21 0.22-6.76 
CSP 3.14 (low titer) 
1.31 (high titer) 
1.44-6.87 
1.04-1.64 
 
HRP11 
 
1.13 (low titer) 
1.43 (high titer) 
   
0.43-2.93 
0.27-7.60 
LSA1 3.32 (low titer) 
1.48 (high titer) 
1.09-10.1 
0.28-7.77 
MSP1  3D7 1.27 0.74-2.18 
MSP1 FUP 9.03 (low titer) 
0.95 (high titer) 
1.16-70.3 
0.33-2.72 
MSP1 FVO 1.35 (low titer) 
0.82 (high titer) 
0.52-3.47 
0.33-2.02 
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Figure 5:  Logistic regression analysis: Odds of antibody being associated with severe 
malaria, adjusted for age.  X axis shows Odds Ratio on logarithmic scale.  Y axis 
shows the malaria antigen associated with the antibody.  Upper graph shows odds 
ratios for IgM, lower graph shows OR for IgG. 
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Figure 3.6: IgG and IgM data in uninfected infants 0-6 months of age (maternal antibody)  
(top panel), in patients with first episode of malaria (middle panel) and in patients with recurrent 
 malaria infection (bottom panel). 
 37 
 
Immunological Profiling 
Serum samples from all patients enrolled in our study were analyzed using a 
multiplex immunoassay to determine which anti-malaria antibodies were present 
in this population.  
  
Our results show that several anti-malarial IgG antibodies were significantly 
associated with severe malaria in our study population. IgG antibodies to AMA-1, 
HRP2, Celtos and the MSP-1 allelic variants were elevated in hospitalized 
patients with malaria (Table 3.3) compared to outpatients.  Since these patients 
were admitted with severe malaria, it is not likely that they were effective in 
fighting off the infection.   IgG antibodies to the pre-erythrocyte antigens, LSA-1 
and CSP, were not significantly associated with severe malaria in hospitalized 
patients (Figure 3.5).  
  
In contrast, IgM antibody levels to LSA-1 and CSP were significantly elevated 
and associated with severe disease compared to uncomplicated infections (Table 
3.4, Figure 3.5). IgM to other malaria antigens were not significantly associated 
with severe malarial disease. 
 
We examined the presence of IgG and IgM anti-malarial antibodies in infants 
younger than 6 months of age and with no prior history of infection, in order to 
identify which maternal antibodies were present in this population.  We also 
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identified which anti-malarial IgG and IgM antibodies were present with initial and 
recurrent infection, to try to learn more about the development of anti-malarial 
immunity in this population (Figure 3.7). Antibody associated with initial infection 
demonstrates which antibodies are responding to an initial challenge with 
malaria. IgG antibodies present with recurrent infections could be involved with 
the development of premunition. 
 
Infant less than 6 months of age with no known prior history of malaria by parent 
report, showed elevated levels of IgG to MSP-1, AMA and HRP2 antigens, but 
had low levels of LSA1 and CSP IgG.  IgM to HRP2 and MSP1 were also noted 
to be elevated in the 0-6 month old patients.  This most likely is an indication that 
the infants are being bitten by infective mosquitoes but may not become 
symptomatic because of maternal IgG antibody protection. 
 
In patients with initial infection by parent report, IgM to all malaria antigens that 
were tested was found to be present. In comparing to figure 3.5, IgM to LSA-1 
and CSP (at lower level titer) is significantly associated with severe infection, 
raising the possibility that these IgM antibodies show potential as diagnostic tool, 
indicative of severe infection. IgG antibodies  
 
 39 
 
   
 
 
 
 
 
 
 
 
 
Table 3.6: Correlation Coefficients  IgM vs IgG  in RDT positive patients 
(Pearson r,  p values) 
 IgG 
AMA-1 
IgG 
CeLTOs 
IgG 
CSP 
IgG 
HRP2 
IgG 
LSA-1 
IgG 
MSP-1 
3D7 
IgG 
MSP-1 
FUP 
IgG 
MSP-1 
FVO 
IgM 
AMA-1 
(r, p value) 
0.04 
0.56 
0.07 
0.29 
0.08 
0.25 
0.05 
0.44 
0.05 
0.50 
0.09 
0.17 
0.09 
0.17 
0.08 
0.21 
IgM 
Celtos 
(r, p value) 
0.05 
0.50 
0.43 
0.53 
-0.03 
0.70 
<0.01 
0.91 
<-0.01 
0.68 
0.08 
0.27 
0.07 
0.30 
0.07 
0.78 
IgM 
CSP 
(r, p value) 
0.06 
0.34 
0.11 
0.10 
<0.01 
0.96 
0.11 
0.13 
0.10 
0.13 
0.12 
0.07 
0.12 
0.08 
0.11 
0.11 
 
IgM 
HRP2 
(r, p value) 
-0.02 
0.745 
0.15 
0.02 
0.21 
<0.01*** 
0.04 
0.55 
0.06 
0.40 
0.18 
0.01** 
0.17 
0.01* 
 0.19 
<0.01** 
IgM 
LSA-1 
(r, p value) 
0.01 
0.07 
0.11 
0.09 
<0.01 
0.51 
0.01 
0.11 
0.11 
0.30 
0.12 
0.90 
0.12 
0.07 
0.13 
0.69 
IgM 
MSP-1 3D7 
(r, p value) 
0.02 
0.78 
0.08 
0.24 
0.24 
<0.01*** 
0.01 
0.85 
0.12 
0.08 
0.17 
0.01* 
0.15 
0.02* 
0.20 
<0.01** 
IgM 
MSP1-FUP 
(r, p value) 
0.04 
0.59 
0.11 
0.12 
0.25 
<0.01*** 
0.03 
0.62 
0.14 
<0.01 
0.21 
<0.01** 
0.20 
0.04* 
0.25 
<0.01*** 
IgM 
MSP-1 FVO 
(r, p value) 
0.11 
0.11 
0.16 
0.12* 
-0.01 
0.92 
0.09 
0.20 
0.12 
0.74 
0.12 
0.08 
0.12 
0.07 
0.14 
0.04* 
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Table 3.7: Correlation Coefficients  IgM vs IgG  in RDT negative patients 
(Pearson r,  p values) 
 IgG 
AMA-1 
IgG 
CeLTOs 
IgG 
CSP 
IgG 
HRP2 
IgG 
LSA-1 
IgG 
MSP-1 
3D7 
IgG 
MSP-1 
FUP 
IgG 
MSP-1 
FVO 
IgM  
AMA-1 
(r, p value) 
0.28 
<0.01*** 
0.40 
<0.01*** 
0.35 
<0.01*** 
0.31 
<0.01*** 
0.32 
<0.01*** 
 
0.45 
<0.01*** 
 
0.46 
<0.01*** 
0.46 
<0.01*** 
IgM 
Celtos 
(r, p value) 
0.16 
0.02* 
0.19 
0.01** 
0.22 
<0.01*** 
0.20 
<0.01** 
0.067 
0.32 
0.24 
<0.001*** 
0.25 
<0.001*** 
0.24 
<0.01*** 
IgM 
CSP 
(r, p value) 
0.32 
<0.01*** 
0.48 
<0.01*** 
0.22 
<0.01*** 
0.40 
<0.01*** 
0.15 
<0.03* 
0.44 
<0.01*** 
0.46 
<0.01*** 
0.46 
<0.01*** 
IgM 
HRP2 
(r, p value) 
0.01 
0.90 
0.11 
0.11 
0.10 
0.16 
0.04 
0.56 
0.03 
0.68 
0.11 
0.09 
0.11 
0.12 
0.11 
0.12 
IgM 
LSA-1 
(r, p value) 
0.28 
<0.01*** 
0.43 
<0.01*** 
0.46 
<0.01*** 
0.39 
<0.01*** 
0.31 
<0.01*** 
0.48 
<0.01*** 
0.48 
<0.01*** 
0.48 
<0.01*** 
IgM 
MSP-1 3D7 
(r, p value) 
0.069 
0.31 
0.13 
0.05 
0.12 
0.08 
0.063 
0.35 
0.26 
<0.01*** 
0.24 
<0.01*** 
0.23 
<0.01*** 
0.25 
<0.01*** 
IgM 
MSP1-FUP 
(r, p value) 
0.11 
0.10 
0.16 
0.02* 
0.14 
0.03* 
0.087 
0.20 
0.30 
<0.01*** 
0.20 
<0.01*** 
0.28 
<0.01*** 
0.30 
<0.01*** 
IgM 
MSP-1 
FVO 
(r, p value) 
0.03 
0.70 
0.07 
0.31 
0.08 
0.24 
-0.09 
0.79 
0.14 
0.04* 
0.14 
0.046 
0.13 
0.05* 
0.16 
0.02* 
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responding to MSP-1, AMA and HRP2 antigens were elevated in these children. 
In patients with recurrent infection, IgG responding to MSP-1, HRP2 and AMA 
antigens were again found to be elevated. 
 
We examined the correlations between IgG antibodies and IgM antibodies 
present in both RDT positive and RDT negative patients (Table 3.6).  Patients 
who were RDT positive, and who had IgM present (indicating initial immune 
response to a new malaria antigen) had lower numbers of IgG antibodies present 
 
In RDT negative patients, when IgM was present, indicating an initial immune 
response mounted to a challenge with new malaria antigens, there were a 
number of IgG antibodies responding to this new infection (Table 3.7). This may 
represent patients with recurrent infection, who have developed an immune 
response and can respond with IgG quickly, and thus are fighting off recurrent 
infection.  
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Chapter IV. Discussion 
 
In resource-limited settings, such as Liberia, it is presumed that the majority of 
patients do not seek hospital care, due to distance and expense. In these regions 
there are few diagnostic resources available to help to distinguish malaria from a 
myriad of other febrile illnesses.  Distinguishing malaria from other causes of 
febrile illnesses can be useful in identifying those children who need referral for 
hospital management and alternative treatments other than anti-malarial drugs. 
 
We undertook this pilot study to learn more about how severe malaria presents in 
this population and whether we could identify factors associated with severe 
disease in young children 5 and under.  To our knowledge, there have been no 
recent studies that describe the clinical features of severe malaria in Liberian 
children.  We identified several factors that may help identify children who are at 
risk for severe disease and could be incorporated into a diagnostic algorithm. Our 
results are consistent with other studies of severe malaria in African children from 
other countries and may shed light on ways to improve differential diagnoses of 
acute febrile illnesses. 
 
Clinical and Demographic Features of Severe Malaria in Liberian Children 
Consistent with other studies, we found that age is a significant risk factor in this 
population of children who are exposed to constant, high level of malaria 
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transmission. In our population, the mean age of children who were RDT positive 
for malaria was 2.1 years, with children slightly older (mean age 2.4 years) 
needing to be admitted with symptoms of severe malaria. Very young children, 
from age 0-12 months, appeared to have less of a risk of testing positive for 
malaria even when symptomatic. This likely represents the presence of maternal 
IgG antibodies which confers protection from some infections and is thought to 
persist from birth up to 6-9 months of age (19). Thus, infants most likely do not 
have malaria even if the symptoms are presumptive, suggesting that alternate 
diagnoses should be clinically evaluated. In contrast, slightly  older children (1-4 
years) were more likely to have severe malaria, and this finding is consistent with 
waning maternal antibody with persistent exposure to infective mosquitoes (20). 
These results support a recent malaria indicator survey that was performed in 
Liberia in 2011, which also concludes that malaria presents in children with 
varying severity depending on age. (11). 
 
Prior epidemiologic studies of severe malaria have shown that the median age of 
children affected is inversely proportional to transmission intensity (20). In areas 
of intense malaria transmission such as Liberia, younger children with 
undeveloped immunity are more likely to be affected and hospitalized, as was 
seen in our study. In these regions, malaria is a disease of young children from 
birth to about 5 years of age, and older children and adults acquire natural 
immunity after repeated infections (21).  In areas with less intense transmission, 
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older children presenting with impaired consciousness and cerebral malaria may 
predominate (19). Our findings suggest that in Liberia, young children ages 1-3 
years old had the greatest risk of developing severe malaria. 
 
Our finding that only 31% of the population used bed nets regularly is consistent 
with data from the MIS (11).  This survey indicates that while 50% of the 
population owns a bed net, they do not appear to be using them regularly or 
correctly, since only 32% of persons surveyed had slept under a bed net 
regularly. This sample may be biased, however, as this was a hospital based 
study of children presenting with fever, and not a true community based sample.  
It does suggest, however that more aggressive malaria control measures are 
needed in Liberia. Public health measures designed to improve this intervention 
have proven very successful in other malaria endemic regions of the world (22) 
and there is no reason to believe they would not become equally successful, if 
implemented, in Liberia.  However, more country-specific studies are warranted 
to determine if the barriers to bednet use are lack of knowledge of their benefits 
or other challenges such as access or preference, since sleeping under bednets 
in hot humid climates makes them uncomfortable to use. 
 
We also found that approximately 22% of patients had been given antimalarial 
drugs prior to presentation at hospital and this was highly associated with less 
severe malaria compared to children who had not be given prompt treatment. 
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Anti-malarial medications are freely available for purchase in pharmacies in 
Liberia. If accompanied by rapid diagnostic testing prior to administration of anti-
malaria medication, pharmacy diagnosis and prompt treatment could prove to be 
an effective means of preventing cases of severe malaria in children. This is 
encouraging and demonstrates that parents are knowledgeable about malaria 
and seek treatment for their children if symptoms do not resolve.  Future studies 
could address delays in care seeking behaviors of parents and determine if 
RDTs were used by local pharmacies or if the parents presumed their children 
had malaria without confirmation. 
 
We found being from an urban area was associated with severe malaria. 
Because the ability to access to care in rural areas is very challenging in Liberia, 
it is possible that those children with severe disease were unable to reach care in 
urban areas, where most secondary and tertiary facilities are located.  
 
In comparing patients with severe versus uncomplicated malaria, we found that a 
higher percentage of patients with uncomplicated presentations had reported 
prior episodes of malaria. This suggests that children with reported past 
infections had an opportunity to develop semi-protective antimalarial immunity 
that would result in uncomplicated infections compared to those with no reported 
past infections. This finding is consistent with other reports in the literature (20). 
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One of the primary motivations for this pilot study was to determine how many 
presumed malaria infections were caused by malaria, as opposed to another co-
infection (23,24).  The WHO has established criteria for severe malaria, and 
among these, the most commonly seen symptoms that are predictive of severe 
disease and death in children include impaired consciousness, respiratory 
distress, hypoglycemia, acidosis and hyperlactatemia. Other symptoms such as 
prostration, multiple convulsions, and severe anemia were seen frequently in 
children, but had lower prognostic value (25). Our findings are consistent with 
these observations and provided reassurance that clinical signs and symptoms of 
malaria are informative in this setting.  A large number of children in our 
population also presented with symptoms of headache and vomiting, and this 
was highly associated with testing positive for malaria and having severe 
disease. These symptoms have frequently been described in populations 
presenting with malaria, although are not listed as WHO criteria (26, 27). 
 
A large study performed in Kenya in 1995 (28) sought to validate the WHO 
criteria for severe malaria in Kenyan children by tracking treatment response and 
parasite clearance in addition to resolution of symptoms.  Their findings suggest 
that two clinical syndromes of severe malarial disease are present in children: 
malaria with impaired consciousness, suggestive of cerebral malaria, and malaria 
with respiratory distress.  Both of these symptoms, impaired consciousness and 
respiratory distress were highly associated with mortality. Cerebral malaria is 
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more often seen in older children, and respiratory distress, caused by severe 
malarial anemia, is seen in younger children (28). 
 
 
 
Febrile Case Investigations 
Many public health efforts designed to address the management of malaria in 
Africa have concentrated on bringing patients with febrile illness to hospital 
attention, but few studies have examined the accuracy of diagnosis and 
appropriateness of hospital treatment.  Current protocols in use to diagnose 
severe malaria are based on reducing the risk of mortality and are sensitive, but 
not specific (29). Yet the presumptive diagnosis of malaria, and the consequent 
neglect of alternative diagnoses in hospitalized patients have been demonstrated 
to impact morbidity and mortality. A recent prospective hospital based study 
performed in 10 hospitals in Tanzania examined the outcomes for patients 
admitted and treated for severe malaria. This study concluded that patients 
admitted with a diagnosis of malaria who were slide negative were often not 
treated with antibiotics, and had twice the hospital case-fatality rate of their slide 
positive counterparts (30). 
 
Our results support the observation that children who live in high malaria 
transmission zones are over diagnosed with malaria.  Approximately one third of 
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the children in our study who were admitted and treated for severe malaria tested 
RDT negative on admission. Approximately 22% of these children did received 
an antimalarial medication prior to hospital admission, but since the RDT that is 
used in this hospital, which tests for HRP2 antigen, is known to stay positive for 
up to 21 days after diagnosis, it is unlikely that these children were partially 
treated malaria cases.  All were also parasite smear negative. A limitation of this 
study was that few other laboratory investigations were available to ascertain 
alternative causes of illness. Consequently, we noted a four-fold increase in case 
fatality rates in the RDT negative patients versus the RDT positive patients, 
suggesting that their deaths were caused by an alternative, undiagnosed and 
therefore untreated illness. 
 
Alternative Causes of Febrile illness 
The numerous causes of febrile illness in pediatric populations in limited 
resource, tropical countries are often difficult to distinguish by clinical findings 
alone. In African children, febrile illness is the most common reason for 
hospitalization and malaria and invasive bacterial disease are the most common 
etiologies (31).  Other undiagnosed illnesses can mimic the signs and symptoms 
of malaria and present in a similar fashion. These diagnoses may not even be 
considered in children who are admitted and presumed to have severe malaria.  
For example, recent reports from Malawi, Tanzania and Bangladesh, etc. has 
shown the incidence of Dengue virus to be increasing (32, 33).   Dengue virus 
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was recently reported in neighboring Sierra Leone (34). S. Typhii is also a 
common pathogen in African children hospitalized with fever. Patients infected 
with these pathogens display signs and symptoms similar to severe malaria. 
More recently, the Ebola Virus Disease (EVD) outbreak in West Africa posed 
many diagnostic and clinical management challenges, given the common 
presentation of EVD and malaria. Our study was conducted prior to the recent 
Ebola epidemic in Liberia. Therefore, we were not in a position to test the impact 
of such a misdiagnosis on clinical outcomes. However, of the children enrolled in 
our study, most (66%) were indeed diagnosed with malaria.  This underscores 
the continued public health crisis in Liberia and supports continued efforts aimed 
at malaria prevention and control. 
 
Yet, other common childhood infections are simmering just under the surface. 
We screened RDT negative hospitalized patients for S. typhii, a pathogen known 
to be endemic in this population (35). Salmonella typhii presents in a similar 
fashion as malaria, with high fever and vomiting. If left untreated, it can lead to 
intestinal perforation and death. There were 3 children who tested positive for 
this pathogen, making it the likely cause of their illness. These children were all 
over the age of 3 years of age, and presented with high fever and vomiting, signs 
suggestive of both malaria and S. typhii. Unfortunately, our testing was done 
retrospectively since this test was not available in Liberia.  So, none of the 
children received antibiotics which supports our finding that children who are 
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presumed to have malaria are at high risk of being undiagnosed and the true 
cause of their illness left untreated These findings suggest that older children 
who are acutely ill and RDT negative should also be treated empirically for other 
etiologies of threatening illness, using broad spectrum antibiotics, until improved 
diagnostics can be devised.  Point of care rapid diagnostics for S.Typhii exist, but 
have poor sensitivity and specificity, and are not useful in this setting. An 
improved method of diagnosing this disease would be helpful in this setting (36). 
 
We also performed a pilot test to screen the hospitalized RDT negative children 
for Dengue virus, but did not find any cases in this small sample. 
 
Future studies to elucidate all causes of febrile illness will be important to pursue 
in order to improve public health for young children in Liberia. This knowledge will 
inform the development of further point of care testing and treatment algorithms 
for children admitted to the hospital or coming to rural clinics for diagnosis of 
febrile illnesses.  Co-infections with malaria also need to be considered with 
caution and evaluated based on age of the patient since the development of 
premonition allows the persistence of asymptomatic parasitemias.   The 
introduction of diagnostic antibody testing could be useful in distinguishing 
premonition versus true symptomatic infection.  The use of IgM antibody test, for 
example, may indicate first malaria infection and would therefore be treated more 
attentively.  The recent Ebola Virus epidemic in West Africa makes the 
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development of such algorithms even more urgent, since EVD can mimic the 
signs and symptoms of severe malaria at first, and if not accurately diagnosed, 
can lead to the spread of disease throughout hospitals (37). A recent study 
performed in by D’Acremont et al in Tanzania, in an area where malaria 
prevalence is decreasing, has helped to elucidate many pathogens in this setting, 
both viral and bacterial, which cause febrile illness in children in this population 
(39). This approach would be useful in the West African setting, where little is 
known about the different causes of fever in children. 
 
Clearance of Parasites 
The majority of admitted patients (87%) responded to anti-malarial treatment with 
intravenous quinine or artusenate, resolved their symptoms, and were 
discharged home by hospital day 3. However, a total of 19 out of 165 admitted 
patients were noted to have persistent parasitemias on their day 3 blood smear, 
and had not cleared their parasites at the time of discharge. Patients are not 
usually checked for persistence of parasitemia on discharge, so this was a new 
finding. Artemisinin-based compounds are known to have very short half-lives (in 
minutes), so when therapy is stopped, unless patients are compliant with oral 
treatment, they will not clear their parasitemia further. The protocol for treatment 
includes an additional 3-day course of artemisinin-based combination therapy 
(ACT) post discharge, so it is possible that patients cleared their parasites post 
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discharge, but there is no follow up data to support this. Patients do not typically 
follow up for repeat blood smear after their treatment is completed. 
 
There are several reasons why these patients may not have cleared their 
parasitemia.  In sequentially admitted patients who were parasite positive on 
discharge, it is possible that the anti-malarial drug used to treat these patients 
was ineffective, due to circumstances such as expired or counterfeit drugs being 
used.  Nosocomial malaria infection has been known to occur in this setting, but 
unlikely if these children were being treatment for malaria. The development of 
drug resistance, which we were unable to document, is also a possibility. Lastly, 
development of immune tolerance to malaria in these children is also a 
possibility, as it is known that tolerance develops in this age group. 
 
This group of patients who do not clear their parasitemia will be an important 
group to follow in future studies for many reasons. It is well known that malaria 
treatment does not always induce sterilizing immunity, and even though a child 
may no longer suffer the symptoms of malaria or be at risk of death, they can still 
harbor parasites. These children who carry malaria asymptomatically also serve 
as a reservoir to infect others. Therefore, determining if they have cleared their 
infection is of great importance. Furthermore, those children who continue to 
harbor parasites after treatment is complete could be doing so because they are 
developing tolerance to malaria parasites. The mechanisms involved in the 
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development of this tolerance are important in understanding how immunity to 
malaria develops. THIs correlate of protection could be useful in strategies used 
in malaria vaccine development. 
 
Drug Resistance Studies 
Anti-malarial drug resistance mutations that are associated with medications 
such as chloroquine, sulfadoxine pyrimethamin (used for intermittent preventative 
therapy in pregnancy) and other medications have been reported in Africa (39).   
A recent study performed in Liberia found that although treatment is highly 
efficacious, selection of molecular markers in reinfections could indicate a 
decreased sensitivity or tolerance of parasites to the current treatments, and the 
baseline prevalence of molecular markers should be closely monitored. This was 
especially true for the pfmdr polymorphisms after treatment with artemesinin 
combination therapy  (40). More recently, a recent case report from Equatorial 
Guinea suggests that artemisinin resistance may be developing in West Africa  
(41). 
 
A secondary goal of this study was to screen for potential anti-malarial drug 
resistance in children who do not respond to treatment.  We screened 100 
inpatient samples for malaria drug resistance for the pfmdr, pfcrt and Kelch drug 
resistance mutations, but did not detect any of these mutations. Follow up 
studies of the patients who do not clear their parasitemia on discharge, such as 
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the 19 patients that we identified, would have allowed us to determine if their 
parasites had developed drug resistant mutations.  However, this pilot study was 
limited in scope and financing, not to mention that this time frame would have put 
us at the beginning of the Ebola epidemic. 
 
Immunological Profiling 
Natural immunity to malaria develops over time and through repeated infections 
to variant strains circulating in the population. The development of anti-malarial 
antibodies is thought to be important in developing this immunity.  Most serology 
studies measure IgG to malaria antigens as indicators of protection and the 
development of immunologic memory.  An antimalarial sero-profile has also been 
used to indicate a history of past infections and may become a useful tool in 
malaria control and surveillance programs.  However, few studies measure IgM 
antibodies which would indicate new infections.  We examined whether  
measuring IgG and IgM could be used as a better indicator of new malaria 
infections that could become integrated into a diagnostic algorithm.  This would 
complement the RDT, especially in children who were given antimalarial 
treatments prior to coming to the hospital and may still be suffering from their 
malaria infections even after parasites have been cleared. 
 
Infants are thought to have acquired passive anti-malarial immunity at birth from 
the placental transfer of IgG antibodies from their mother that have  been shown 
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to persist for the first 6-9 months of life. At the point when this antibody protection 
starts to wane, children become susceptible to severe disease, as their own 
immunity is developing (indicated by IgM antibodies). As children age and 
((experience repeated)) better descriptor needed, often uncomplicated through 
symptomatic malaria infections, they start to develop premonition (??), 
characterized as being less susceptible to severe disease when infected.  There 
is currently no diagnostic test that indicates on an individual basis when this 
immune tolerance develops and to which malaria antigens this immunity is most 
directed.  
 
Our results suggest that IgM to AMA-1, LSA-1 and CSP are associated with 
severe malarial infections.  These antibodies may also play a role in initial, 
severe infections, since in RDT positive patients, they are elevated and do not 
appear to be correlated with elevations in  IgG antibody.  These antibodies may 
be useful in distinguishing which patients may be experiencing initial, severe 
infection from those who have had malaria in the past, and have developed 
tolerance. 
 
Our study identified several anti-malaria IgG antibodies that are present in 
Liberian children who were admitted with severe malaria, such as IgG antibodies 
to AMA-1, HRP2, Celtos and the MSP-1 allelic variants. These antibodies have 
been shown to correlate with protection in other populations (42, 43); however, 
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since they are often found in hospitalized patients, it is unlikely that they 
conferred adequate protection from developing severe malaria.  We found 2 
antibodies, IgG responding to LSA1 and CSP, that were not elevated in patients 
with severe malaria.  It is possible that the lack of these antibodies could be 
associated with lack of protection, and that these particular antibodies confer 
protection from severe malaria. The patients with severe malaria may not have 
developed the ability to produce these antibodies. 
 
 Many of the children had IgG to blood stage and transmission blocking antigens. 
Since many of our patients were very young, this IgG may represent passive 
immunity acquired through maternal antibody.  Severe malaria was also 
significantly associated with IgM antibody responding to two pre-erythrocytic 
antigens, CSP and LSA -1.  It is possible that the addition of antibody titers to 
these antigens could improve diagnosic capabilities, especially in recently treated 
children who are determined to be RDT negative. 
 
Study Strengths and Limitations 
Strengths of this study include the fact that, to our knowledge, this is the first 
study investigating the demographic and clinical characteristics of malaria in 
Liberian children since their second civil war which began in 1999. Our data are 
also novel in that they were collected prior to the EVD epidemic, and may be 
helpful in establishing baseline characteristics of this population. 
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Our pilot study had several limitations that need to be kept in mind in interpreting 
the study results.  We worked with a relatively small sample of patients who were 
referred to, and treated at, the national referral hospital.  This population of 
patients may not be representative of the Liberian population as a whole, so we 
do not know if our results are generalizable 
Our limited budget prevented full exploration of WHO signs and symptoms of 
malaria, such as hyperglycemia, acidosis, and hyperparasitemia. These lab 
investigations are not routinely performed on patients at JFK Medical Center; 
therefore we were not able to validate symptoms with clinical diagnostics.  We 
were also unable to screen for other types of pathogens known to be prevalent in 
African children, such as non-typhoid salmonella, and Strep pneumococcus. 
 
Loss of sample integrity and inability to get all of our samples out of Liberia due 
to the EVD epidemic prevented complete assessment of antibiotic resistance in 
those children who did not clear their parasitemia 
 
Future Directions 
This pilot study points us to several important future studies including the 
following: 
 
Development of diagnostic and therapeutic algorithms for children 
presenting with fever and suspected malaria in resource limited settings. 
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Algorithms which target those at risk for severe malaria, and which provide for 
treatment of alternative illness in children who test negative for malaria need to 
be developed. New diagnostics may help to further differentiate those children 
who are at highest risk.  
 
 
Elucidation of the alternative causes of acute febrile illness providing better 
understanding of full spectrum of febrile illness in Liberian children.  As we 
demonstrated, there is a higher case -fatality rate in hospitalized children who 
test negative for malaria. A better understanding of alternative causes of illness 
will help improve the overall outcomes for children under 5 years – a Millennium 
Goal for the WHO. Given the fact that Ebola is now endemic in West Africa, the 
development of algorithms and clinical guidelines to immediately differentiate the 
many causes of febrile illness is critical. 
 
Investigation of the development of immune tolerance to malaria in young 
children.  A follow up cohort study to better understand the interplay of passive 
immunity in neonates, and the development of natural immunity in young children 
in areas of high malaria transmission will help to identify potential antigenic 
targets for malaria vaccines. 
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Investigation of drug resistance A study targeting children who do not clear 
their parasites after treatment would be useful to screen for drug resistance 
mutations, and to better understand the mechanisms involved in the 
development of drug resistance in young children. 
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Appendix I:  Data Collection Sheet 
Malaria Study:  Data Collection Sheet 
 
Study ID #: 
 
Demographic information:                                    Date of admission:__________ 
 
MR #________________DOB________         Sex:    Male________Female_________ 
 
County:____________________     % of time bednet used __________  Not used_____ 
 
Pre Hospital information: 
 
Number of times treated for malaria _________Number of times in hospital___________ 
 
Type of malaria medication Used Prior to this Admission (for this illness):  
 
Number of days with fever prior to admission: ________ 
 
Other illnesses________________ 
 
Symptoms/Signs on admission: 
 
Headache_____      Prostration/weakness_______   Loss of consciousness_________ 
 
Pallor________       Seizures__________                 Cough________ 
 
Respiratory Distress_________Diarrhea_________Jaundice_________ 
 
Labs on admission: 
     
Rapid Diagnostic Test: ____positive____negative___Not done   
 
Level of Parasitemia by smear_:   1+___   2+___   3+ ___  4+  ___ 
 
Blood glucose_____mg/dl     Hemoglobin level______mg/dl    Spot 
test:_____pos___neg 
 
 
Discharge Information: 
 
Level of Parasitemia by smear:  1+___  2+___ 3+___  4+___ 
 
Other diagnoses in addition to malaria: 
________________________________________ 
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Antimalarial Medication used _____________      Antibiotics used__________________  
 
Blood transfusion required?:   Yes_____No____ 
 
Number of days until clinical status improved______Number of days in hospital_______ 
 
Disposition: Home   _____feeding center ______   expired _____other hospital ______ 
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